SS-31: The Cardiolipin-Targeting Mitochondrial Peptide
Last updated: March 2026
SS-31 (Elamipretide, MTP-131) is a synthetic tetrapeptide that binds directly to cardiolipin — a phospholipid found only in the mitochondrial inner membrane — stabilizing the electron transport chain and protecting mitochondrial architecture. It is one of the most clinically advanced mitochondria-targeted therapeutics. In September 2025 it became the first mitochondria-targeted drug ever FDA-approved — as FORZINITY, for Barth syndrome.
(tetrapeptide)
mito-targeted drug
Designations
How SS-31 Works: Cardiolipin Binding
SS-31's mechanism is unusually specific — it targets a single molecular target found exclusively in one cellular organelle. This selectivity is what makes it different from general antioxidants or mitochondrial support supplements.
Cardiolipin is a unique anionic phospholipid found only in the mitochondrial inner membrane. It constitutes ~20% of the inner membrane's lipid composition. SS-31's alternating aromatic and basic residues (D-Arg-dimethylTyr-Lys-Phe-NH₂) give it high affinity for cardiolipin's negatively charged head groups.
By binding cardiolipin, SS-31 stabilizes the cristae architecture and electron transport chain supercomplexes (Complexes I, III, IV). This is critical — ETC complex instability is the root cause of reduced ATP production and increased ROS in mitochondrial disease states.
Cardiolipin normally anchors cytochrome c to the inner membrane as an electron carrier. When cardiolipin is oxidized (peroxidized), cytochrome c detaches, releases into cytoplasm, and triggers apoptosis. SS-31 prevents cardiolipin peroxidation, keeping cytochrome c in its functional role.
Dysfunctional ETC complexes "leak" electrons to molecular oxygen, producing superoxide and downstream reactive oxygen species. By stabilizing Complex I and III, SS-31 reduces electron leak and decreases mitochondrial ROS production — without simply scavenging free radicals.
Healthy cristae (the inner folds of the mitochondrial inner membrane) are essential for efficient ATP synthesis. Cardiolipin maintains cristae curvature. In mitochondrial disease and heart failure, cristae collapse and become disorganized. SS-31 restores cristae architecture even in aged or diseased mitochondria.
SS-31 is administered subcutaneously or intravenously in clinical trials. Its alternating charge pattern facilitates rapid cell penetration independent of membrane potential — meaning it works even in cells with collapsed mitochondrial membrane potential (i.e., the sickest mitochondria).
Why Mitochondrial Dysfunction Matters
Mitochondrial dysfunction is implicated in an enormous range of diseases — from rare genetic disorders to common age-related conditions like heart failure, Parkinson's, and Type 2 diabetes.
Clinical Trial Results & FDA Approval
SS-31/Elamipretide has one of the deepest clinical development programs of any mitochondria-targeted peptide — culminating in FDA accelerated approval for Barth syndrome in September 2025. Key trials across multiple indications.
The TAZPOWER trial enrolled 12 patients with Barth syndrome — a rare X-linked cardiomyopathy caused by TAZ gene mutations resulting in defective cardiolipin remodeling. This is the most direct indication for SS-31 given the direct cardiolipin pathology.
Primary mitochondrial myopathy (PMM) is a rare inherited disease causing progressive muscle weakness and exercise intolerance due to ETC dysfunction. The MMPOWER-3 Phase 3 trial was terminated after missing its co-primary endpoints.
Heart failure is strongly associated with mitochondrial dysfunction in cardiomyocytes, and several studies examined elamipretide's effect on cardiac function and exercise capacity. The dedicated Phase 2 program has since been discontinued.
Retinal pigment epithelial cells are among the most metabolically demanding cells in the body and are highly dependent on mitochondrial function. Geographic atrophy (dry AMD) involves significant mitochondrial damage in these cells. This is now elamipretide's only genuinely active late-stage program outside Barth syndrome.
What the Numbers Show
Quantified outcomes from published Phase 2/3 trials. All data from peer-reviewed sources; cross-trial comparisons carry inherent limitations.
The Pipeline Story: From Lab to Clinic
SS-31 has one of the most turbulent but also most advanced development stories of any peptide in the mitochondrial space — and, as of September 2025, a case study in how a mitochondria-targeted peptide reached FDA approval.
Dr. Hazel Szeto at Weill Cornell Medical College synthesizes a series of Szeto-Schiller (SS) peptides targeting mitochondrial membranes. SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH₂) shows the strongest cardiolipin-binding affinity and mitochondrial protection in preclinical models.
Patent rights licensed to Stealth BioTherapeutics (Boston). The compound is renamed Elamipretide (INN) / MTP-131 internally. Stealth raises substantial venture capital and begins IND submissions. Initial human Phase 1 data shows favorable safety.
Stealth runs parallel Phase 2 trials — MMPOWER (mitochondrial myopathy), PROGRESS-HF (heart failure), ReCLAIM (dry AMD), and the Barth syndrome program. FDA grants Orphan Drug Designation for Barth syndrome and PMM. Early signals emerge across several indications, though several trials later miss their primary endpoints.
TAZPOWER completes: its randomized placebo-controlled crossover phase did not meet the primary endpoints, but the open-label extension showed significant 6MWT and symptom improvements at 36 weeks. Stealth's MMPOWER-3 pivotal trial in PMM also misses its primary endpoint in the original analysis (large placebo effect), and the company undergoes significant financial restructuring. Plans for a US IPO are shelved.
After a 2024 FDA advisory committee voted 10–6 that elamipretide is effective for Barth syndrome, a May 2025 Complete Response Letter, and an August 2025 resubmission, the FDA granted accelerated approval on September 19, 2025 — elamipretide as FORZINITY for Barth syndrome (NDA 215244), the first-ever Barth therapy and the first FDA-approved mitochondria-targeted drug. Approval was based on improved knee-extensor muscle strength, an intermediate endpoint. FORZINITY launched via specialty pharmacy in December 2025.
The sponsor rebranded from Stealth BioTherapeutics to Mighty Therapeutics on June 16, 2026, and closed up to $150M in financing on July 14, 2026, extending runway into 2028. The confirmatory Phase 3b/4 trial 4TAZPower (NCT07531251) is underway to verify clinical benefit and support continued approval, while the Phase 3 ReNEW trial in dry AMD remains active (not recruiting).
Who Is SS-31 For? Ideal Candidates
SS-31 is not a general wellness compound — it is a disease-state intervention aimed at pathological mitochondrial dysfunction. Understanding who benefits most is critical to interpreting the data.
- Barth syndrome patients (TAZ mutation, cardiolipin deficiency)
- Primary mitochondrial myopathy (ETC complex defects)
- Mitochondrial cardiomyopathy, MELAS, LHON patients
- Heart failure with documented mitochondrial dysfunction
- Research models: ischemia-reperfusion injury
- Post-cardiac surgery (acute mitochondrial stress)
- Healthy aging optimization (no human data)
- Athletic performance enhancement
- General longevity / anti-aging supplementation
- Neurological diseases without primary mito-pathology
- Any condition without documented mitochondrial dysfunction
- Use without diagnosis or medical supervision
Clinical Safety Data
Across 7+ clinical trials and hundreds of patients, elamipretide has demonstrated a consistent safety profile. Here's what the trials show.
SS-31, Humanin & MOTS-c: Three Mitochondrial Angles
SS-31 belongs to a broader class of mitochondria-targeting peptides. While Humanin and MOTS-c are endogenous peptides encoded by mitochondrial DNA, SS-31 is a synthetic peptide that mimics cardiolipin's binding partners.
Target: Cardiolipin (inner membrane)
Mechanism: ETC complex stabilization, ROS reduction, cristae preservation
Status: FDA-approved (FORZINITY, Barth syndrome) — most advanced
Origin: Synthetic tetrapeptide (not endogenous)
Target: IGFBP3, BAX, tBID (anti-apoptotic)
Mechanism: Cytoprotection, insulin sensitization, neuroprotection
Status: Preclinical only — no human trials
Origin: Endogenous 24-AA peptide from mitochondrial 16S rRNA
Target: AMPK pathway, nuclear gene regulation
Mechanism: Metabolic reprogramming, glucose utilization, anti-aging
Status: Phase 1 trials initiated
Origin: Endogenous 16-AA peptide from mitochondrial 12S rRNA
SS-31 & Vision: What the Eyesight Buzz Gets Right — and Wrong
In August 2026 a wave of X and TikTok posts began crediting SS-31 with sharper eyesight — some users self-reporting reduced astigmatism, crisper focus, or "younger" vision within weeks. There is a real, peer-reviewed mitochondrial-vision thread underneath the hype. There is also a large gap between what that research shows and what the anecdotes claim. Here is the honest split.
In aged mice, spatial (photopic) visual acuity declined to ~40% below normal by 34 months of age. Daily elamipretide — applied systemically or as an eye drop — mitigated that decline, and when started after acuity had dropped ~16%, it reversed the loss and normalized function within about two months, with benefit persisting for months after withdrawal. The authors were explicit that this is a rationale to investigate whether mitochondrial dysfunction is a treatable driver of human visual aging — not proof that it is. This is neural/retinal function in mice, not human refraction. Alam et al., Dis Model Mech 2022 · PMID 34766182
ReCLAIM-2 (NCT03891875), a 176-patient Phase 2 trial in adults ≥55 with dry AMD and geographic atrophy, did not meet either co-primary endpoint — including its low-luminance visual-acuity endpoint. It did show a signal on a structural biomarker: a 43% reduction in progression of complete ellipsoid-zone (photoreceptor) loss (nominal P=0.0034). That photoreceptor signal is what seeded the Phase 3 ReNEW trial (NCT06373731), currently active but not recruiting. In other words: the best human evidence to date failed on visual acuity and only hinted at slowing retinal degeneration. Ehlers et al., Ophthalmol Sci 2024 · PMID 39605874
- Retinal pigment epithelium and photoreceptors are among the most mitochondria-dependent cells in the body, so a cardiolipin-targeting peptide has a biologically plausible retinal rationale
- In aged mice, elamipretide mitigated and even reversed age-related photopic acuity/contrast-sensitivity decline (Alam et al. 2022, PMID 34766182)
- In humans, ReCLAIM-2 (Phase 2, dry AMD) produced a photoreceptor/ellipsoid-zone preservation signal (43% reduction in complete EZ loss, nominal P=0.0034)
- The only genuinely late-stage eye program is Phase 3 ReNEW in dry AMD (NCT06373731) — a specific retinal disease, run under medical supervision
- No controlled human data supports astigmatism reversal or refractive-error improvement — astigmatism is corneal/lens shape, outside SS-31's mechanism entirely
- ReCLAIM-2 missed both co-primary endpoints, including visual acuity — human eyesight "gains" are not established
- No trial has tested SS-31 for sharpening vision in healthy or simply "aging" eyes; the human target is AMD, a disease
- The reversal-of-decline data is in mice; the authors themselves framed it only as a rationale to investigate humans
- Self-reported eyesight improvements online are anecdote (uncontrolled, unblinded, no acuity measurement) — not evidence we endorse
Study Citations
Key Takeaways
- FDA-approved as FORZINITY for Barth syndrome via accelerated approval (Sept 19, 2025) — the first FDA-approved mitochondria-targeted drug (NDA 215244); 40 mg SC once daily for patients ≥30 kg
- Tetrapeptide with high specificity for cardiolipin in the mitochondrial inner membrane
- Stabilizes ETC complexes I, III, IV — improves ATP production efficiency
- TAZPOWER Phase 2/3: open-label 36-week 6MWT improvement of +95.9m (p=0.024) in Barth syndrome; the randomized crossover phase did not meet its primary endpoints — this data supported the 2025 approval
- Early-phase signal in mitochondrial myopathy (MMPOWER Phase 1/2: +64.5m 6MWT at highest dose)
- FDA Orphan Drug Designation for Barth syndrome and PMM
- Consistent, favorable safety profile across 7+ clinical trials
- Administered SC — formulated for human use
- Approval is for Barth syndrome ONLY — not approved for any other indication, and remains investigational for all non-Barth uses
- Continued approval is contingent on the confirmatory 4TAZPower trial (NCT07531251), which is still recruiting
- Approval rested on an intermediate endpoint (knee-extensor muscle strength), not a confirmed clinical-outcome benefit
- MMPOWER-3 Phase 3 in PMM was terminated (co-primary endpoints missed); no active registrational PMM trial
- Heart-failure program discontinued after PROGRESS-HF missed its primary endpoint vs placebo
- Long-term safety data beyond ~18 months not established
- Efficacy in healthy aging / longevity untested in humans (an investigator-initiated Phase 2 study, SHAPE / NCT07275424, is listed as recruiting)
- Optimal dosing for different disease states not fully defined
- Oral bioavailability is poor — requires injection
🛒 Mitochondrial Support Products
Clinically-researched mitochondrial support supplements and peptide research essentials.
Affiliate links — support HighPeptides at no extra cost.
🔗 Related Resources
Frequently Asked Questions
What is SS-31 (Elamipretide)?
SS-31 (Elamipretide, MTP-131) is a synthetic tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that specifically binds cardiolipin in the mitochondrial inner membrane. It was developed by Dr. Hazel Szeto at Cornell and licensed to Stealth BioTherapeutics (now Mighty Therapeutics). In September 2025 it became FORZINITY — the first FDA-approved mitochondria-targeted drug.
How does SS-31 work?
SS-31 binds directly to cardiolipin — a phospholipid unique to the mitochondrial inner membrane. This stabilizes electron transport chain (ETC) complexes I, III, and IV, prevents cristae collapse, reduces reactive oxygen species (ROS) production, and maintains cytochrome c in its electron carrier role rather than triggering apoptosis.
What diseases is SS-31 being trialed for?
Elamipretide is FDA-approved (as FORZINITY) for Barth syndrome; its confirmatory Phase 3b/4 trial, 4TAZPower (NCT07531251), is recruiting. For dry age-related macular degeneration, the Phase 3 ReNEW trial (NCT06373731) is active but not recruiting — the only late-stage trial currently ongoing. The primary mitochondrial myopathy trials (MMPOWER-3 terminated; NuPOWER completed Dec 2024) leave no active registrational PMM study, and the Phase 2 heart-failure program (PROGRESS-HF) is completed with the program discontinued. Elamipretide holds FDA Orphan Drug designation for Barth syndrome and PMM.
Is SS-31 FDA approved?
Yes — for one indication. On September 19, 2025 the FDA granted accelerated approval to FORZINITY (elamipretide) for Barth syndrome, making it the first-ever therapy for Barth syndrome and the first FDA-approved mitochondria-targeted drug (NDA 215244). Approval was based on improved knee-extensor muscle strength, an intermediate endpoint, with a confirmatory trial (4TAZPower) underway. It is approved for Barth syndrome only (adult and pediatric patients weighing at least 30 kg; 40 mg subcutaneously once daily) and remains investigational for all other uses.
Who developed SS-31?
SS-31 was invented by Dr. Hazel Szeto at Weill Cornell Medical College. The patent was licensed to Stealth BioTherapeutics, a Boston-based biotech that has been privately held since a 2022 buyout. The company rebranded to Mighty Therapeutics in June 2026 and closed up to $150M in financing in July 2026. It secured FDA accelerated approval for elamipretide (FORZINITY) in Barth syndrome in September 2025.
What is the safety profile of SS-31?
In clinical trials, SS-31 has demonstrated a favorable safety profile. The most common adverse events are mild injection-site reactions. No dose-limiting toxicity has been observed at therapeutic doses. Serious adverse events were not significantly different from placebo in Phase 2 trials.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide — $19 (normally $29) →
New to peptides? Start with the $19 Buyer’s Playbook →
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
This page is for educational and informational purposes only. SS-31 (Elamipretide) is FDA-approved as FORZINITY for Barth syndrome only (accelerated approval, September 2025). It is NOT approved for any other indication, for self-administration, or for general wellness use, and remains investigational for all non-Barth uses. All clinical data presented comes from published peer-reviewed trials in specific patient populations with mitochondrial diseases. Cross-trial comparisons carry inherent limitations. Nothing on this page constitutes medical advice. Always consult a qualified physician before starting any new substance.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars — metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.